35.91

1.07% 0.38

After Hours: 35.89 -0.02 -0.06%

Artivion Inc (AORT)

Overview News Price History Option Chain Discussions Forecast Stock Split Dividend History

Artivion Inc stock is traded at $35.91, with a volume of 284.13K. It is up +1.07% in the last 24 hours and up +5.09% over the past month. Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

Previous Close:

$35.53

Open:

$35.54

24h Volume:

284.13K

Relative Volume:

0.66

Market Cap:

$1.74B

Revenue:

$441.33M

Net Income/Loss:

$9.76M

P/E Ratio:

179.73

EPS:

0.1998

Net Cash Flow:

$839.00K

1W Performance:

-1.16%

1M Performance:

+5.09%

6M Performance:

-22.79%

1Y Performance:

+51.07%

1-Day Range:

$34.70

$36.13

1-Week Range:

$34.24

$36.79

52-Week Range:

$24.53

$48.25

Artivion Inc Stock (AORT) Company Profile

Name

Artivion Inc

Sector

Healthcare (1106)

Industry

Medical Devices (142)

Phone

(770) 419-3355

Address

1655 ROBERTS BOULEVARD N W, KENNESAW

Employee

1,800

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

AORT's Discussions on Twitter

Compare AORT vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AORT Artivion Inc	35.91	1.72B	441.33M	9.76M	839.00K	0.1998
ABT Abbott Laboratories	87.17	152.48B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	295.25	111.40B	25.27B	3.34B	4.57B	8.6358
MDT Medtronic Plc	77.79	100.53B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	55.98	84.50B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	82.91	48.04B	6.30B	1.07B	1.34B	1.8406

Artivion Inc Stock (AORT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Upgrade	Ladenburg Thalmann	Neutral → Buy
Aug-13-25	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-17-25	Initiated	Canaccord Genuity	Buy
Oct-23-24	Initiated	JMP Securities	Mkt Outperform
Sep-27-22	Reiterated	Lake Street	Buy
Aug-08-22	Initiated	Lake Street	Buy
Mar-03-22	Initiated	Stifel	Buy

View All

Artivion Inc Stock (AORT) Latest News

May 05, 2026

Artivion Q1 2026 Earnings Preview — May 7, Street Expects $0.12 EPS - AlphaStreet

May 05, 2026

May 02, 2026

Earnings Preview: Artivion to Report Financial Results Post-market on May 07 - Moomoo

May 02, 2026

May 01, 2026

Freedom Capital Markets initiates Artivion stock with buy rating By Investing.com - Investing.com Australia

May 01, 2026

Freedom Capital Markets initiates Artivion stock with buy rating - Investing.com

May 01, 2026

Apr 30, 2026

Conestoga Capital Adds Artivion to Portfolio Amid Market Volatility - HarianBasis.co

Apr 28, 2026

Strong Catalysts Drive Artivion (AORT) - Insider Monkey

Apr 28, 2026

Apr 27, 2026

What are the risks of Artivion (AORT) stock today | Artivion Logs 40% EPS Miss Below Analyst EstimatesMoat - Newser

Apr 27, 2026

Apr 25, 2026

Artivion (NYSE:AORT) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat

Apr 25, 2026

Apr 23, 2026

Artivion's next earnings update lands May 7, with a 4:30 p.m. ET webcast - Stock Titan

Apr 23, 2026

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results - marketscreener.com

Apr 23, 2026

AORT (Artivion Inc.) shares fall 1.26% after Q4 2025 EPS lands 40% below consensus analyst estimates.Social Investment Platform - Cổng thông tin điện tử tỉnh Lào Cai

Apr 23, 2026

AORT (Artivion) shares climb 2.86 percent on the day despite a 40 percent Q4 2025 EPS miss versus analyst estimates.Retail Trader Ideas - Xã Thanh Hà

Apr 23, 2026

Apr 22, 2026

Price Action Overview | Artivion posts 40% EPS miss below Street estimatesPerformance Review - UBND thành phố Hải Phòng

Apr 22, 2026

Artivion (AORT) Stock: Price Action Overview | Artivion posts 40% EPS miss below Street estimatesPerformance Review - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Artivion, Inc. (NYSE:AORT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Apr 22, 2026

Apr 21, 2026

Will FDA Approval Of NEXUS And Endospan Option Reshape Artivion's (AORT) Minimally Invasive Aortic Strategy - simplywall.st

Apr 21, 2026

Apr 20, 2026

Artivion (AORT) Gains Conviction List Spot with Strong Buy Ratin - GuruFocus

Apr 20, 2026

Artivion, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo

Apr 20, 2026

Apr 18, 2026

Artivion shows improved relative strength; still shy of benchmark - MSN

Apr 18, 2026

Apr 16, 2026

How The Investment Story Is Shifting For Artivion (AORT) After Recent Analyst And FDA Updates - Yahoo Finance

Apr 16, 2026

Artivion (AORT) Stock: Why It Matters This Year (-1.95%) 2026-04-16Crowd Risk Alerts - UBND thành phố Hải Phòng

Apr 16, 2026

Apr 14, 2026

Assessing Artivion (AORT) Valuation After FDA Approval Of NEXUS Aortic Arch System - simplywall.st

Apr 14, 2026

Apr 11, 2026

Tudor Investment Corp ET AL Sells 39,388 Shares of Artivion, Inc. $AORT - MarketBeat

Apr 11, 2026

Artivion (NYSE:AORT) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat

Apr 11, 2026

Apr 10, 2026

Artivion secures FDA approval for NEXUS aortic arch device, weighs Endospan acquisition - MSN

Apr 10, 2026